tiprankstipranks
Trending News
More News >
Resverlogix Corp. J (TSE:RVX)
TSX:RVX

Resverlogix (RVX) Price & Analysis

Compare
32 Followers

RVX Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.68%99.32%
Mutual Funds
― Other Institutional Investors
99.32% Public Companies and
Individual Investors

RVX FAQ

What was Resverlogix Corp. J’s price range in the past 12 months?
Resverlogix Corp. J lowest stock price was C$0.04 and its highest was C$0.10 in the past 12 months.
    What is Resverlogix Corp. J’s market cap?
    Resverlogix Corp. J’s market cap is C$11.37M.
      When is Resverlogix Corp. J’s upcoming earnings report date?
      Resverlogix Corp. J’s upcoming earnings report date is Aug 19, 2025 which is in 70 days.
        How were Resverlogix Corp. J’s earnings last quarter?
        Currently, no data Available
        Is Resverlogix Corp. J overvalued?
        According to Wall Street analysts Resverlogix Corp. J’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Resverlogix Corp. J pay dividends?
          Resverlogix Corp. J pays a Notavailable dividend of C$0.4 which represents an annual dividend yield of N/A. See more information on Resverlogix Corp. J dividends here
            What is Resverlogix Corp. J’s EPS estimate?
            Resverlogix Corp. J’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Resverlogix Corp. J have?
            Resverlogix Corp. J has 284,263,900 shares outstanding.
              What happened to Resverlogix Corp. J’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Resverlogix Corp. J?
              Currently, no hedge funds are holding shares in TSE:RVX

              Company Description

              Resverlogix Corp. J

              Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
              Similar Stocks
              Company
              Price & Change
              Follow
              Kane Biotech
              Britannia Life Sciences Inc
              Tetra Bio-Pharma
              BetterLife Pharma
              BioVaxys Technology
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis